The two anticoagulants are associated with similar mortality rates. However, a new meta-analysis in Circulation may have cardiologists favoring bivalirudin over heparin. 

What are the latest updates on treating tricuspid regurgitation? We spoke with a leading researcher at ESC Congress 2023 to find out. 

The biggest differences between the two treatment options were major bleeding events and all-cause mortality. There was no significant difference when it came to stroke risk. 

Interventional cardiologists with Henry Ford Health performed the historic procedure on an 85-year-old patient who had been experiencing worsening symptoms for a full year.

“Our results beg the question of whether pre-TAVR baseline coronary angiography is even necessary,” researchers wrote in the American Journal of Cardiology.

The new device, the first of its kind to gain FDA approval, was designed for patients who have no other endovascular or surgical options available to them.

Shockwave and two other healthcare companies in the cardiovascular health space are considered attractive options for investors looking to expand their portfolios. 

Researchers explored data from more than 2,300 patients, categorizing all bleeding events based on updated VARC-3 definitions. The team's final analysis was published in JACC: Cardiovascular Interventions.